key: cord-0688748-v51k81ie
authors: Irsara, C.; Egger, A. E.; Prokop, W.; Nairz, M.; Loacker, L.; Sahanic, S.; Sonnweber, T.; Mayer, W.; Schennach, H.; Loeffler-Ragg, J.; Bellmann-Weiler, R.; Tancevski, I.; Weiss, G.; Anliker, M.; Griesmacher, A.; Hoermann, G.
title: Evaluation of four commercial, fully automated SARS-CoV-2 antibody tests suggests a revision of the Siemens SARS-CoV-2 IgG assay
date: 2020-11-30
journal: nan
DOI: 10.1101/2020.11.27.20239590
sha: 7efb2c006207ab4af40e54c3f7843b79c87265d0
doc_id: 688748
cord_uid: v51k81ie

Objectives: Serological tests detect antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in the ongoing coronavirus disease-19 (COVID-19) pandemic. Independent external clinical validation of performance characteristics is of paramount importance. Methods: Four fully automated assays, Roche Elecsys Anti-SARS-CoV-2, Abbott SARS-CoV-2 IgG, Siemens SARS-CoV-2 total (COV2T) and SARS-CoV-2 IgG (COV2G) were evaluated using 350 pre-pandemic samples and 700 samples from 245 COVID-19 patients (158 hospitalized, 87 outpatients). Results: All tests showed very high diagnostic specificity. Sensitivities in samples collected at least 14 days after disease onset were slightly lower than manufacturers' claims for Roche (93.04%), Abbott (90.83%), and Siemens COV2T (90.26%), and distinctly lower for Siemens COV2G (78.76%). Concordantly negative results were enriched for immunocompromised patients. ROC curve analyses suggest a lowering of the cut-off index for the Siemens COV2G assay. Finally, the combination of two anti-SARS-CoV-2 antibody assays is feasible when considering borderline reactive results. Conclusions: Thorough on-site evaluation of commercially available serologic tests for detection of antibodies against SARS-CoV-2 remains imperative for laboratories. The potentially impaired sensitivity of the Siemens COV2G necessitates a switch to the company's newly filed SARS-CoV-2 IgG assay (sCOVG) for follow-up studies. A combination of tests could be considered in clinical practice.

transcription polymerase chain reaction (RT-PCR) (6, 7) . However, molecular methods have some limitations, in particular the relatively short time frame of detectability post symptom onset and thus possible false negative results in patients who present with low viral load at later stages of the disease course (8) (9) (10) . In contrast, the presence of SARS-CoV-2 antibodies indicates a recent or prior exposure to the virus (11) . Serological tests are therefore important to assess the seroprevalence for monitoring the epidemiology of SARS-CoV-2 infection at the population-level. In view of a still relatively low seroprevalence in many countries, specificities of the assays are crucial for epidemiologic studies and the positive predictive value of a result (12) . Furthermore, serologic testing in addition to PCR may aid to increase the accuracy of diagnosis, in particular when seroconversion is documented in consecutive blood samples (8, 13) .

Moreover, SARS-CoV-2 antibody tests are used to select eligible donors for convalescent plasma (14). Finally, serologic tests are used in SARS-CoV-2 vaccine studies to estimate the immunological response to vaccination (15) . The durability of the antibody response as well as the extent and duration of immunity against reinfection with SARS-CoV-2 are still under investigation (16) .

Immune response to SARS-CoV-2 includes cell-mediated (17) and antibody-mediated immunity (13) . The SARS-CoV-2 genome encodes four major structural proteins, the spike (S), envelope (E), membrane (M) and nucleocapsid (N) proteins, and several accessory proteins (18, 19) . The S protein with its receptor-binding domain (RBD) and the N protein are widely used as antigens to assess the humoral immune responses by detection of specific antibodies (20) (21) (22) . Serological assays currently used include neutralizing antibody assays, enzyme-linked immunosorbent assays (ELISA), automated chemiluminescence immunoassays (CLIA) and lateral flow immunoassays (LFIA) (21, 23) . Distinct serologic assays detect different antibody isotypes: IgG, IgM, . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020. 11.27.20239590 doi: medRxiv preprint IgA or all isotypes simultaneously ("total antibodies"). ELISA and CLIA raw data are often calculated as index (in relation to a known sample such as provided control material) and reported as positive or negative depending on a predefined cut-off value.

A rapidly growing number of commercial SARS-CoV-2 antibody assays is available.

Whereas the manufacturer of an in vitro diagnostic (IVD) device is obliged to declare performance specifications of the test, the need for independent validation of commercial assays in clinical settings has been highlighted in systematic reviews of the literature (24, 25) . On the one hand, medical laboratories have to verify that they meet the performance specifications. On the other hand, small sample sizes and a lack of samples from patients with mild to moderate clinical course represent a potential bias in performance studies (26, 27) . Our study aimed to evaluate four SARS-CoV-2 antibody assays on three fully automated large-scale laboratory analyzers manufactured by Abbott, Roche, and Siemens, respectively. To or knowledge this is the first published external validation of the Siemens SARS-CoV-2 IgG (COV2G) antibody test.

The present study was performed at the Central Institute of Clinical and Chemical Laboratory Diagnostics at the University Hospital of Innsbruck as part of the clinical evaluation of different SARS-CoV-2 serologic assays. All procedures performed in the present study involving human participants were in accordance with the ethical standards of the Institutional and/or National Research Committee and with the 1964 Helsinki declaration and its later amendments and were approved by the ethics committee of . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.27.20239590 doi: medRxiv preprint toid arthritis) drawn before the COVID-19 era were examined. Additionally, an intravenous immunoglobulin formulation (Privigen®, 100 mg/ml, CSL Behring AG, Bern, Switzerland) composed of pre-pandemic pooled immunoglobulins (mainly IgG) of a large number of healthy donors from the US, which should by definition yield negative SARS-CoV-2 antibody results, was used for antibody assay evaluations.

Blood samples were drawn according to routine clinical procedures. Upon centrifugation, serum specimens for antibody determination were kept at 4°C if analyses were conducted within 7 days or stored at -20°C in the case analyses were conducted at a later time point. Frozen samples were thawed and centrifuged prior to antibody determination.

We evaluated the performance of the following fully automated CLIA tests on high throughput random access analyzers widely available in medical laboratories: Roche is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.27.20239590 doi: medRxiv preprint with the specified controls and calibrators by trained laboratory staff. Test characteristics given in the manufacturers' product information are summarized in Supplemental   Table S1 .

Specificity was analyzed on 350 archived samples drawn in the pre-COVID-19 era and sensitivity on samples from patients with RT-PCR confirmed SARS-CoV-2 infection.

Only one sample per patient was subjected to sensitivity analysis to avoid bias due to multiple testing. Patients were included if at least one sample dating between day 14 and day 120 after disease onset was available. In case of multiple samples available per patient, the sample closest to day 28 was included in the sensitivity analysis.

Statistical analyses were performed using MedCalc, version 11.5.1.0 (MedCalc Ltd., Ostend, Belgium) and Excel 2016 (Microsoft, Redmont, USA). Median and interquartile range (IQR) were used as descriptive measures of metric data. Categorical data are given as counts and percentages. 95% confidence intervals (CI) for proportions were calculated according to the Clopper-Pearson exact method. The difference between categorical data was assessed using Chi-square test (McNemar's test for paired data, "N-1" Chi-squared test for unpaired proportions). Receiver operating characteristic (ROC) curve analysis was performed using the DeLong method. The concordance correlation coefficient was calculated according Lin. Statistical significance was defined at a level of 0.05.

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.27.20239590 doi: medRxiv preprint

Of the 350 pre-pandemic samples included, 341 were analyzed with the Roche Elecsys Anti-SARS-CoV-2 assay, 298 with Abbott SARS-CoV-2 IgG, 288 with Siemens SARS-CoV-2 total (COV2T), and 191 with Siemens SARS-CoV-2 IgG (COV2G). Using the manufacturers' cut-offs, the specificity ranged from 99.33% to 100.00% (Roche 99.71%, Abbott 99.33%, Siemens COV2T 99.65%, Siemens COV2G 100.00%; Table   2 , Supplemental Table S2 ). The small number of false positive samples (Supplemental Table S3 ) showed no overlap between the tests as none of the samples was tested positive in more than one assay. No false positive result was observed in the subcohorts of pre-pandemic samples from patients with bacterial pneumonia (n=51) or rheumatologic diseases (n=25). Borderline cross reactivity when measuring undiluted intravenous immunoglobulin formulation (Privigen®) was found only for Siemens SARS-CoV-2 IgG (Index: 1.09). However when diluting Privigen® 1:50 with SARS-CoV-2 negative serum or sodium chloride 0.9% (reflecting a more physiological immunoglobulin concentration) all assays shielded negative results (Supplemental Table   S4 ).

From 230 (93.9%) of the 245 PCR-confirmed COVID-19 patients, a sample dating between day 14 and day 120 after disease onset was available for analysis. The median time between disease onset and blood sampling was 46 days (IQR 24-62, range 14-120; Table 1 , Supplemental Figure S1 ). All single results of the 230 samples are shown in Supplemental Table S5 . Using the manufacturers' cut-offs, the observed sensitivity of the assays ranged from 78.76% to 93.04% (Roche Elecsys Anti-SARS-CoV-2 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.27.20239590 doi: medRxiv preprint 93.04%, Abbott SARS-CoV-2 IgG 90.79%, Siemens SARS-CoV-2 total 90.26%, Siemens SARS-CoV-2 IgG 78.76%; Table 2, Supplemental Table S6 ). Compared to the COV2G assay, the Roche (p<0.0001), Abbott (p=0.0001) and COV2T (p<0.0001) tests were significantly more sensitive.

In an exploratory analysis, we assessed the sensitivity of the assays stratified for gender, age, and disease severity (Supplemental Table S6 ). When stratifying for gender, sensitivity was higher for males than for females within the Abbott (male: 94.52%, female: 84.15%; p=0.0095) and Siemens COV2G (male: 87.30%, female: 62.69%; p=0.0001) assays ( Figure 1A ). Stratified for patient age, sensitivity for Siemens COV2G was lower in the age group 18-49 years (63.93%) compared to patients aged 50-69 years (86.32%) and 70-100 years (83.78%) ( Figure 1B) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.27.20239590 doi: medRxiv preprint assay (one was positive only in the Abbott and one only in the Siemens COV2T test).

Seven out of those 15 patients were under immunosuppressive treatment not related to COVID-19. Of those, three were under ongoing chemotherapy due to malignancy, two patients had ongoing anti-CD20 therapy with obinutuzumab or rituximab due to lymphoma, one patient received methotrexate due to rheumatoid arthritis and another is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2020. Table S8 ). When comparing the ROC curves, the AUC of the COV2G test was significantly smaller than the AUC of Roche (p=0.0151) and Abbott (p=0.0174).

In an exploratory analysis, we asked if the assay cut-offs could be modified to improve the sensitivity. The proposed cut-off indexes (COI) based on the maximum sum of sensitivity and specificity in ROC curve analysis were below the manufacturers' COI: Table S9 ).

Concordance between results of different antibody assays indicates a potential for test combinations When considering all 1,050 samples the concordance correlation coefficient between the four assays ranged from 77.45% to 92.49% (Supplemental Table S10 ). Of the 350 pre-pandemic samples included in our study, 235 were tested with all three assays. 233 of these samples (99.1%) were tested negative with all three assays. In two (0.9%) . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.27.20239590 doi: medRxiv preprint samples, only the Abbott test yielded a positive result. To compare the sensitivity of the assays in detail, we restricted the analysis to a single sample per patient obtained between day 14 and day 120 after disease onset as described above. 189 samples of PCR-confirmed COVID-19 patients were tested with the four assays Roche, Abbott, and Siemens (COV2T and COV2G). 145 (76.7%) of them were positive with all four assays, and 11 (5.8%) were found negative in all four assays. Of note, 18 samples (9.5%) were negative only with COV2G ( Figure 4 ). Due to the unexpected low sensitivity of the Siemens COV2G test, we restricted further analyses on combinatorial approaches to the three assays Roche Elecsys Anti-SARS-CoV-2, Abbott SARS-CoV-2

IgG and Siemens SARS-CoV-2 total (COV2T).

Finally, we asked whether a combination of two antibody tests could be useful to further improve the clinical performance of serologic SARS-CoV-2 tests. When combining any two out of the Roche, Abbott and Siemens COV2T assays, specificity improves to 100.00%, regardless of the combination used. However, sensitivity dropped to <90% when considering only samples with concordantly positive results in both tests (Table   3 ). When we used the modified COI instead of the manufacturers' COI, sensitivity of the combinations improved to 95.18% for Roche and Abbott (manufacturers' COI: 89.91%), 92.31% for Roche and Siemens COV2T (manufacturers' COI: 89.23%), and 92.27% for Abbott and Siemens COV2T (manufacturers' COI: 86.60%). In contrast, the specificity of the combined analyses was not affected by the lowering of the COI (Table 3 ).

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020. 11.27.20239590 doi: medRxiv preprint In the present study we examined the performance characteristics of four fully automated SARS-CoV-2 antibody CLIA assays focusing on high throughput random access analyzers widely available in many medical laboratories. While the specificity of all assays was well comparable to the performance characteristics provided by the manufacturers, we observed a markedly lower sensitivity in our cohort (78.76% to 93.04% compared to >99%). Similar results have been found in other studies for the Roche, Abbott and the Siemens COV2T assays (28, 29) . These findings emphasize the importance of real life data and different clinical scenarios in independent assay validations. While the more subtle differences between observed and expected sensitivity rates for Roche, Abbott and Siemens COV2T were coherent within our study and might be explained by specific characteristics of our patients cohort, the sensitivity of Siemens COV2G was markedly lower in our hands with 78.76% in the total cohort and 64.86% in outpatients. To the best of our knowledge, our study is the first public-available independent evaluation of the COV2G assay and warrants further studies to verify and potentially improve the performance of this test. ROC curve analysis of our results of the Siemens COV2G assay suggests that the cut-off might be too high. Indeed, a number of false negative samples showed borderline reactivity that did not exceed the manufactures' assay cut-off of 1.0. Lowering the cut-off to 0.32 would improve the sensitivity from 78.76% to 89.64% with modest effect on the assay specificity (100.00% to 97.38%). Of course, this post-hoc change of the cut-off would require to repeat the evaluation of sensitivity and specificity for the Siemens COV2G assay in a large cohort.

Indeed, the company has just recently filed an FDA-application for approval of a new SARS-CoV-2 IgG assay (sCOVG) with improved sensitivity. Our results indicate that potential differences in the assay performance between the Siemens COV2G and the is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.27.20239590 doi: medRxiv preprint new sCOVG assays need to be considered when evaluating sequential samples of patients.

Interestingly, we found lower sensitivities in female vs. male patients with all four assays, whereby a statistical significant difference was found only in the Abbott and Siemens COV2G assays. In a sub-analysis this trend for a gender difference was found in all three different courses of disease (outpatient, general ward, ICU; data not shown). IgM (in-house) antibody response and disease severity, however, patients were segregated in ICU vs. non-ICU care and unlike to the study of Plebani and our study no asymptomatic or outpatient populations, respectively, were described separately (32).

The importance of including patients with mild disease course in antibody evaluation studies has already been highlighted (26) . We did not observe a major difference between the positivity rates for outpatients, hospitalized patients and ICU patients for the Roche, Abbott and the Siemens COV2T assays. In contrast, the sensitivity rates for the Siemens COV2G were significantly lower in outpatients compared to hospitalized patients. The stringent cut-off of this particular assay might affect the results in patients with low antibody levels. However, none of the assays evaluated was optimized for is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.27.20239590 doi: medRxiv preprint quantification of antibody titers and quantitative analysis was limited by the dynamic range of the tests. Thus, our study was not designed to assess quantitative differences in antibody levels between patients.

Notably, absence of reactivity in serological assays could either reflect antibody test performance or the biological absence of antibodies in individuals as no clear gold standard for the evaluation of SARS-CoV-2 antibody tests exists (33). As samples from 13 patients (5.7%) were constantly negative in all assays, we conclude that the biolog- is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.27.20239590 doi: medRxiv preprint Italy (31) . Thus, a very high diagnostic specificity of serologic tests is crucial to minimize false positive results and improve the positive predictive value (PPV). In line with the performance characteristics provided by the manufacturers, we observed a false positive rate <1% for all tests using samples from the pre-pandemic era. However, even a small false positive rate substantially effects the PPV in a low-prevalence situation (12) . It has thus been suggested to combine the results of two different SARS-CoV-2 antibody tests to further improve specificity and PPV of serologic testing (37) .

As a prerequisite for this strategy, it has been shown that the vast majority of false positive results occurred independently with singular anti-SARS-CoV-2 CLIA assays whereas systematic false positive samples affecting multiple assays are very rarely observed (12) . This is also in line with our observation. Although the number of false positive samples in our study is rather small, we observed not a single sample being false positive in more than one CLIA assay. In contrast, the concordance of false negative samples between the Roche, Abbott and Siemens COV2T assays was rather high and yielded in a combined sensitivity of >86% for any of these combinations.

While singular tests have been optimized for maximal specificity, a combinatorial testing approach could allow to lower the thresholds to recognize borderline reactive samples without impairing specificity. With the lower cut-offs according to the ROC analysis, the combined sensitivity improved to >92% for any combination. These results suggest, that borderline reactive results slightly below the threshold of the test could benefit from further analyses with additional CLIA or ELISA assays. However, due to the huge impact of the disease prevalence and pretest probability on predictive values of the assay results, the purpose of the test (detection or exclusion of disease, seroprevalence studies) should be defined before adjustment of thresholds or combining different serologic tests in a certain setting (38) . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.27.20239590 doi: medRxiv preprint Limitations of our study include differences in the time between disease onset and serological assessment between patients due to the retrospective design of this assay validation study. To avoid potential biases, we constrained our analysis to samples drawn ≥14 days after onset of COVID-19 specific symptoms in SARS-CoV-2 RT-PCR confirmed patients or two weeks after the first positive RT-PCR result in patients for whom no information on symptom onset was available. The median time of 46 days between disease onset and date of the sample used for the sensitivity analysis fits well to the reported plateau of antibody production against SARS-CoV-2 (39). Thus, our study was designed to assess the maximal sensitivity of antibody tests ≥14 days and did not include the early phase of antibody production within the first days of COVID-19. Potential differences between the performances of the evaluated tests in the symptomatic phase of the disease can thus not be excluded. Likewise, the maximum time between disease onset and sampling was 120 days. The duration of antibody produc- (42) . However, among others, the observed discrepancies may also be due to differences in the serologic assays used in the different studies. In our study, no substantial decrease of seropositivity was found within 120 days after disease onset. Further studies are needed to assess the performance of different serological tests in longitudinal analysis. In this regard, quantitative measurements of antibody titers and neutralization or pseudo-neutralization assays will be useful to monitor the course of the is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.27.20239590 doi: medRxiv preprint humoral immune response against SARS-CoV-2 in detail. Another limitation of our study was that only adult patients with COVID-19 have been included. For example, Pierce et al. found that serum neutralizing antibody titers were higher in adults compared to pediatric patients with COVID-19 (43) . Additional studies are needed to evaluate the performance of the assays tested here for children.

In summary, we independently evaluated the performance of four widely available commercial SARS-CoV-2 antibody assays in an adult COVID-19 cohort including both patients with critical to severe as well as mild courses of the disease. While all assays met the desired specificity criteria, we observed a substantially lower sensitivity compared to the performance reported by the manufacturers. Our study emphasizes the importance of achieving additional performance data in real life including specific populations like immunocompromised patients and asymptomatic carriers. Importantly, our results suggest a limited sensitivity of the Siemens COV2G assay that will be replaced by the newly filed Siemens sCOVG assay. In conclusion, a growing number of fully automated SARS-CoV-2 antibody CLIA assays with sufficient performance characteristics is available for different high throughput analyzers. The selection of specific assays and the interpretation of results should carefully reflect the use case, and a combination of different SARS-CoV-2 antibody assays might be useful. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.27.20239590 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.27.20239590 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2020. ; is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.27.20239590 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.27.20239590 doi: medRxiv preprint

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted November 30, 2020. ; https://doi.org/10.1101/2020.11.27.20239590 doi: medRxiv preprint

A Novel Coronavirus from Patients with Pneumonia in China

Clinical Characteristics of Coronavirus Disease 2019 in China

The Rate of Underascertainment of Novel Coronavirus (2019-nCoV) Infection: Estimation Using Japanese Passengers Data on Evacuation Flights

Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape

Laboratory diagnosis of coronavirus disease-2019 (COVID-19)

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore

Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing

Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19

Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin Infect Dis. 2020. 14. safety. ECD-gfhaf. An EU programme of COVID-19 convalescent plasma collection and transfusion. Guidance on collection, testing, processing, storage, distribution and monitored use

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature. 2020. 18. Yoshimoto FK. The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19

The Laboratory Diagnosis of COVID-19 Infection: Current Issues and Challenges

Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends. Diagnostics (Basel

Review of Current Advances in Serologic Testing for COVID-19

Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients

Performance Characteristics of Four High-Throughput Immunoassays for Detection of IgG Antibodies against SARS-CoV-2

Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis

Antibody tests for identification of current and past infection with SARS-CoV-2

Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers

Antibody responses in mild COVID-19 hospital staff

Comparison of the diagnostic sensitivity of SARS-CoV-2 nucleoprotein and glycoprotein-based antibody tests

Differences in Performance Characteristics Among Four High-Throughput Assays for the Detection of Antibodies Against SARS-CoV-2 Using a Common Set of Patient Samples

SARS-CoV-2 IgG and IgA antibody response is gender dependent; and IgG antibodies rapidly decline early on

SARS-CoV-2 Antibody Responses Do Not Predict COVID-19 Disease Severity

Seroprevalence of SARS-CoV-2 immunoglobulin antibodies in Wuhan, China: part of the city-wide massive testing campaign

SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states

Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of

Multi-platform Comparison of SARS-CoV-2 Serology Assays for the Detection of COVID-19

Towards the rational utilization of SARS-CoV-2 serological tests in clinical practice

Response of anti-SARS-CoV-2 total antibodies to nucleocapsid antigen in COVID-19 patients: a longitudinal study

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Antibody responses against SARS-CoV-2 in COVID-19 patients

Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients

Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients